Inhibitors of Receptor for Advanced Glycation-End products (RAGE) for treatment of liver cancer

The receptor for advanced glycation-end prod-ucts (RAGE) has been shown to play a central role not only in acute or chronic inflammatory diseases but also in septic shock, late diabetes and cancer. Here we provide a new application of RAGE inhibition in the field of cancer prevention and treatment.

Further Information: PDF

DKFZ (German Cancer Research Center, Deutsches Krebsforschungszentrum)
Phone: +49-6221-42 2955

Contact
Dr. Ruth Herzog

Media Contact

info@technologieallianz.de TechnologieAllianz e.V.

All latest news from the category: Technology Offerings

Back to home

Comments (0)

Write a comment

Newest articles

A universal framework for spatial biology

SpatialData is a freely accessible tool to unify and integrate data from different omics technologies accounting for spatial information, which can provide holistic insights into health and disease. Biological processes…

How complex biological processes arise

A $20 million grant from the U.S. National Science Foundation (NSF) will support the establishment and operation of the National Synthesis Center for Emergence in the Molecular and Cellular Sciences (NCEMS) at…

Airborne single-photon lidar system achieves high-resolution 3D imaging

Compact, low-power system opens doors for photon-efficient drone and satellite-based environmental monitoring and mapping. Researchers have developed a compact and lightweight single-photon airborne lidar system that can acquire high-resolution 3D…

Partners & Sponsors